Immunology expert and Hudson Institute Research Group Head, Claudia Nold, has received an academic promotion to Associate Professor from Monash University.
Associate Professor Nold is co-head of the research group ‘Interventional Immunology for Neonatal Diseases and Beyond’ within The Ritchie Centre (Hudson Institute and Monash University). She leads the group alongside her husband and laboratory co-head, A/Prof Marcel Nold.
A pharmacist by training, A/Prof Nold has broad research expertise in cytokine biology, inflammation and immunology.
A/Prof Nold says she feels very honoured to gain promotion for her work on finding treatments for the most serious diseases of newborn babies.
“As a Mum myself, nothing in science would give me greater pleasure than to help other families experience the joy of healthy children,” A/Prof Nold, a Heart Foundation Future Leader Fellow, said.
A/Prof Nold undertook her PhD at the Pharmazentrum Frankfurt, Germany, after her graduation from pharmacy school in 2000. Her PhD included a six-month tenure at the Institute of Asthma and Allergy at the Karolinska Institute, Stockholm, Sweden.
From 2006 to 2009, A/Prof Nold held a postdoctoral position in Denver, Colorado, USA in the laboratory of Professor Charles A. Dinarello.
In 2009, A/Prof Nold was recruited to The Ritchie Centre at the Hudson Institute of Medical Research, where she published work revealing the powerful anti-inflammatory properties of the cytokine interleukin 37 (IL-37).
In 2016, the Nold team, together with Monash University collaborators, signed a landmark research collaboration with Swiss-based healthcare company, Roche, to develop next-generation treatments for autoimmune diseases.
A/Prof Nold’s team is also working to develop a safe and effective treatment for two of the major scourges of preterm infants, namely the chronic cardiopulmonary diseases bronchopulmonary dysplasia and pulmonary hypertension.
In 2013 and 2017, A/Prof Nold’s team published seminal studies describing the therapeutic effectiveness of interleukin 1 receptor antagonist (IL-1Ra) for treating bronchopulmonary dysplasia and is now planning a clinical trial to prove the concept in babies.
In conclusion A/Prof Nold said – “I wish to thank my team, my collaborators and most especially my husband Marcel Nold and my mentor Philip Berger for their continuous support”.
Dr Claudia Nold
- Research Group Head, Interventional Immunology in Neonatal Diseases
Hudson Institute Communications
t: + 61 3 8572 2697